Cardlytics (CDLX) Given New $25.00 Price Target at JPMorgan Chase & Co.
Cardlytics (NASDAQ:CDLX) had its price target trimmed by JPMorgan Chase & Co. from $31.00 to $25.00 in a research report report published on Wednesday morning. The brokerage currently has an overweight rating on the stock.
CDLX has been the subject of a number of other research reports. Morgan Stanley reduced their price target on Cardlytics from $28.00 to $26.00 and set an overweight rating for the company in a report on Wednesday. Bank of America reissued a hold rating and issued a $22.00 price target on shares of Cardlytics in a report on Friday, August 17th. Zacks Investment Research downgraded Cardlytics from a hold rating to a sell rating in a report on Tuesday, October 9th. KeyCorp reduced their price target on Cardlytics from $30.00 to $28.00 and set an overweight rating for the company in a report on Wednesday, August 15th. Finally, SunTrust Banks reissued a buy rating and issued a $27.00 price target on shares of Cardlytics in a report on Tuesday, September 11th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $24.29.
Shares of NASDAQ CDLX traded down $0.07 on Wednesday, hitting $13.66. The company had a trading volume of 519,748 shares, compared to its average volume of 172,540. Cardlytics has a 12-month low of $11.10 and a 12-month high of $28.29. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.24 and a quick ratio of 2.24. The company has a market capitalization of $370.43 million and a price-to-earnings ratio of -1.70.
In related news, COO Lynne Marie Laube sold 1,349 shares of the stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $20.66, for a total value of $27,870.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Polaris Venture Management Co. sold 150,000 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $25.04, for a total value of $3,756,000.00. The disclosure for this sale can be found here. Insiders sold 155,194 shares of company stock valued at $3,863,308 in the last three months.
A number of hedge funds and other institutional investors have recently made changes to their positions in CDLX. California State Teachers Retirement System acquired a new stake in Cardlytics during the first quarter valued at approximately $122,000. California Public Employees Retirement System acquired a new stake in Cardlytics during the first quarter valued at approximately $146,000. Wells Fargo & Company MN raised its stake in Cardlytics by 72.4% during the third quarter. Wells Fargo & Company MN now owns 8,004 shares of the company’s stock valued at $201,000 after buying an additional 3,361 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in Cardlytics during the second quarter valued at approximately $214,000. Finally, Rockefeller Capital Management L.P. acquired a new stake in Cardlytics during the third quarter valued at approximately $231,000. Hedge funds and other institutional investors own 53.48% of the company’s stock.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.